Drug Profile
EpiCyte
Latest Information Update: 09 Jul 2013
Price :
$50
*
At a glance
- Originator EpiGenesis Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 09 Jul 2013 Discontinued - Preclinical for Acute myeloid leukaemia in USA (unspecified route)
- 03 Feb 2000 Profile reviewed but no development has been reported recently
- 03 Feb 2000 No-Development-Reported for Acute myeloid leukaemia in USA (Unknown route)